スリランカにおける2型糖尿病患者の若年および高齢者の低血糖に関する比較的多センター横断研究
Priyamali Thusharika Jayasekera1, Thamarasi Senaratne2, Dilusha Lamabadusuriya1
1Department of Medicine, Faculty of Medicine, General Sir John Kotelawala Defence University, Colombo, Sri Lanka.
Journal of diabetes research
|September 2, 2025
まとめ
低血糖症は糖尿病の頻繁な合併症であり,生活の質に影響を与え,深刻な健康リスクをもたらす. 高齢者や弱い人は 症状がより深刻で 患者の教育と管理戦略の必要性を強調しています
科学分野:
- 内分泌学
- 糖尿病の管理
- 公衆衛生
背景:
- 低血糖症は糖尿病治療の 認識されていない合併症です
- 軽度な生活の質の低下から,心臓血管や脳血管などの生命を脅かす出来事まで様々です.
研究 の 目的:
- スリランカの成人糖尿病患者の低血糖症の流行と特徴を調査する.
- 低血糖症の危険因子と患者の管理戦略を特定する.
主な方法:
- スリランカの19の政府病院で2005人の成人糖尿病患者を対象とした多中心の横断的な研究です.
- 人口統計,糖尿病歴,合併症,低血糖エピソード,および管理に関するアンケートによって収集されたデータ.
主要な成果:
- 参加者の67. 3%が過去1年間に少なくとも1回の低血糖症状を経験し,34. 2%が入院を必要とした.
- 高齢者 (≥65歳) や弱い個体では,症状のある低血糖が有意に多く報告されました.
- 常見の原因は食事のスキップ,糖分を減らす食品の摂取,誤った薬剤/インスリン投与などです. 低血糖状態での運転も懸念されました.
結論:
- 低血糖症は,この集団における糖尿病管理における重要かつ一般的な問題です.
- 薬剤の投与が類似しているにもかかわらず,高齢で弱い患者は特に脆弱です.
- 低血糖症の予防,治療,および運転に関連するリスクに関する患者の教育は極めて重要です.
関連する概念動画
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Diabetes: Symptoms, Diagnosis, and Complications
685
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
685
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
Oral Hypoglycemic Agents: Sulfonylureas
320
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
320
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256


